Summary The growth inhibitory effect of tumour promoters on human leukaemia and lung cancer cell lines was examined using the [3-(4,5 dimethylthiazol)-2, 5-diphenyl-tetrazolium bromide (MTT) assay. The four cell lines used were the K562 human leukaemia cell line, its adriamycin (ADM)-resistant subline (K562/ADM), which shows the mdr phenotype, PC-9 (a human lung adenocarcinoma cell line) and its cisplatin (CDDP)-resistant subline (PC-9/CDDP), which does not show the mdr phenotype. Phorbol 12-tetradecanoate-13-acetate (TPA) and the TPA-type tumour promoters, aplysiatoxin and debromoaplysiatoxin, inhibited the growth of the two parental cell lines, K562 and PC-9. The non-TPA-type tumour promoter, okadaic acid, also inhibited the growth of the two parental cell lines in a dose-dependent manner. TPA-type and okadaic acid inhibited the growth of K562/ADM more weakly than that of K562, and showed no growth inhibition in PC-9/CDDP. Anhydrodebromoaplysiatoxin, an inactive derivative of the TPA-type tumour promoter, could suppress the growth of K562 and K562/ADM only at high concentration (more than 50 pM) and it showed similar growth inhibitory effects on the two cell lines. Okadaic acid tetramethyl ether, the inactive form of the non-TPA-type tumour promoter did not inhibit the growth of any of the cell lines. The growth inhibitory effect of these compounds was well correlated with their tumour-promoting activity. A study of the accumulation of okadaic acid revealed that the amount of 3H-okadaic acid in K562/ADM and PC-9/CDDP was similar to that in their parental cells indicating that cross-resistance to this tumour promoter in the drug-resistant cell lines is not due to a difference in the amount of drug accumulated in sensitive and resistant cells. These results suggest the presence of another common mechanism for resistance to ADM and CDDP as well as to TPA-or (Ferguson & Cheng, 1987) . Modulation of drug resistance by TPA is possibly due to phosphorylation of P-glycoprotein, although the modulatory effects are transient (Hamada et al., 1987) . To investigate this, we examined the sensitizing effects of TPA to anticancer drugs using the K562/ADM cell line which possesses the mdr phenotype and its parental cell line K562. Modulatory effects of TPA were not however observed in this assay system (unpublished data). However, in the course of these studies, we observed that TPA showed a growth inhibitory effect on K562 and K562/ADM cells but did not induce differentiation in these cells. Because of this result, we considered that these cells may be useful to study the growth inhibitory effects of tumour promoters in the absence of cell differentiation. We also found TPA to have different inhibitory effects on the growth of parental and drug-resistant cell lines. K562/ADM and PC-9/CDDP revealed cross-resistance to TPA. These data suggested that tumour promoters may be useful compounds in the elucidation of new mechanisms of drug resistance.
Summary The growth inhibitory effect of tumour promoters on human leukaemia and lung cancer cell lines was examined using the [3-(4,5 dimethylthiazol)-2, 5-diphenyl-tetrazolium bromide (MTT) assay. The four cell lines used were the K562 human leukaemia cell line, its adriamycin (ADM)-resistant subline (K562/ADM), which shows the mdr phenotype, PC-9 (a human lung adenocarcinoma cell line) and its cisplatin (CDDP)-resistant subline (PC-9/CDDP), which does not show the mdr phenotype. Phorbol 12-tetradecanoate-13-acetate (TPA) and the TPA-type tumour promoters, aplysiatoxin and debromoaplysiatoxin, inhibited the growth of the two parental cell lines, . The non-TPA-type tumour promoter, okadaic acid, also inhibited the growth of the two parental cell lines in a dose-dependent manner. TPA-type and okadaic acid inhibited the growth of K562/ADM more weakly than that of K562, and showed no growth inhibition in PC-9/CDDP. Anhydrodebromoaplysiatoxin, an inactive derivative of the TPA-type tumour promoter, could suppress the growth of K562 and K562/ADM only at high concentration (more than 50 pM) and it showed similar growth inhibitory effects on the two cell lines. Okadaic acid tetramethyl ether, the inactive form of the non-TPA-type tumour promoter did not inhibit the growth of any of the cell lines. The growth inhibitory effect of these compounds was well correlated with their tumour-promoting activity. A study of the accumulation of okadaic acid revealed that the amount of 3H-okadaic acid in K562/ADM and PC-9/CDDP was similar to that in their parental cells indicating that cross-resistance to this tumour promoter in the drug-resistant cell lines is not due to a difference in the amount of drug accumulated in sensitive and resistant cells. These results suggest the presence of another common mechanism for resistance to ADM and CDDP as well as to TPA-or (Ferguson & Cheng, 1987) . Modulation of drug resistance by TPA is possibly due to phosphorylation of P-glycoprotein, although the modulatory effects are transient (Hamada et al., 1987) . To (Hong et al., 1988) . All cell lines grew in RPMI 1640 medium (Gibco Laboratories, Tokyo Japan) supplemented with 10% fetal bovine serum (Gibco), penicillin (100 U ml-') and streptomycin (100 fg ml-') (RPMI-FBS) in a humidified 5% CO2 atmosphere at 37°C. All cell lines grew mainly as floating aggregates, although PC-9 was also partially attached to the surface of the culture flask. The lines were subcultured once or twice per week.
Tumour promoters TPA and the TPA-type tumour promoters, aplysiatoxin and debromoaplysiatoxin, and a non-TPA-type tumour promoter, okadaic acid, were used in these experiments. Anhydrodebromoaplysiatoxin and okadaic acid tetramethyl ether were used as inactive, control compounds. [27-3HJokadaic acid was synthesised as reported previously (Suganuma et al., 1989) . Tumour promoters were dissolved in dimethyl sulfoxide (DMSO) (Wako Pure Chemical Industries, Ltd., Osaka, Japan) and stored at -70°C until use.
Growth inhibition assay The MTT assay used was essentially the same as that previously reported by Mosmann (1983 (Table II) . The growth inhibitory activities of the other two TPA-type tumour promoters such as aplysiatoxin and debromoaplysiatoxin with moderate tumour promoting activity were tested against the four cell lines (Table II) . Both compounds showed lower growth inhibitory effect on K562, K562/ADM and PC-9 cells than those produced by TPA. From these results, there seems to be some correlation between the growth inhibitory and tumour promoting activity of the tumour promoters.
Correlation between tumour promoting activity and growth inhibiton by tumour promoter in K562 and K562/ADM The correlation between tumour promoting activity and growth Table I inhibition by these compounds was further examined in K562 and K562/ADM cells (Figure 2) . The tumour-promoting activity was expressed as the average numbers of tumours per mouse at 30 weeks of tumour promotion as described in 'Material and methods' and was found to be well correlated with the IC50s in K562 and K562/ADM cells. The correlation coefficients between these two parameters were r = 0.915 and 0.822. There was a similar trend in PC-9/CDDP cells. However, it was impossible to calculate the correlation coefficient because the IC5o value in PC-9/CDDP could not be obtained for the majority of compounds.
Accumulation of 3H-okadaic acid In order to answer the question of whether the sensitivity to a tumour promoter is associated with a difference in drug accumulation, a study of [3H]okadaic acid accumulation was carried out in these four cell lines. Labelled TPA and other TPA-type tumour promoters were not used in this experiment, because the majority of TPA-type tumour promoters bind to membrane located receptors for phorbol ester and thus are not suitable for such a direct accumulation study. There were no differences in the accumulation of 3H-okadaic acid between K562 and K562/ADM (Figure 3 , Table III ) or between PC-9 and PC-9/CDDP (Table III) . The efflux of 3H-okadaic acid (Tsuruo et al., 1986; Fojo et al., 1985; Katner et al., 1983; Ueda et al., 1986) . We confirmed the overexpression of the mdr-l gene in K562/ ADM (Minato et al., 1990) and we demonstrated that efflux of adriamcyin was more than 2-fold greater in K562/ADM than in K562. Although K562/ADM was only 8.4-fold resistant to adriamycin by the MTT assay, it showed about 130-fold resistance in a growth inhibition assay. (Horichi et al., 1990) . These results are consistent with the characteristics of K562/ADM reported by Tsuruo et al. (1986) . On the other hand cisplatin resistance has usually been considered to be multifactorial. We have recently demonstrated that an increase of glutathione (Fujiwara et al., 1990 ) and a decrease in the formation of DNA interstrand crosslinking due to a decreased uptake of cisplatin are both involved in cisplatin resistance. It has however been demonstrated that expression of the mdr-1 gene is not related to cisplatin resistance (Nakagawa et al., 1988) . In the present study, K562/ADM and PC-9/CDDP cells showed cross resistance to TPA-type and non-TPA-type tumour promoters. The inactive derivatives did not, however, produce any effects on the growth of parental and resistant cells except for the high concentration of anhydrodebromoaplysiatoxin in K562 and K562/ADM. We have also demonstrated that growth inhibition by tumour promoters correlates well with their tumour-promoting activity. This result suggests the possibility of a common mechanism for tumour-promoting activity and growth inhibition by tumour promoters. The same phenomenon was observed for both TPA-and non-TPA-type tumour promoters. We therefore consider that TPA-and non-TPA-type tumour promoters may be useful in the elucidation of the common mechanisms of anticancer drug resistance. TPA-type tumour promoters, such as TPA, aplysiatoxin, and debromoaplysiatoxin, activate protein kinase C (PKC) by binding to its phorbol ester binding site (Fine et al., 1988) . Unlike TPA and aplysiatoxin, okadaic acid does not inhibit the specific binding of 3H-TPA to PKC, and does not activate PKC in vitro (Fujiki & Sugimura, 1987) . This is why okadaic acid is classified as a non-TPA-type tumour promoter. PKC is believed to be related to drug resistance because: of the association of a 20-kD phosphoprotein with the mdr phenotype in human breast and small cell lung cancer cell lines (Fine et al., 1985 ; of reversibility of the mdr phenotype by calmodulin antagonists which also inhibit protein kinases (Tsuruo et al., 1983) ; of high baseline PKC activity in an adriamycin-resistant *1 subline of a human nasopharyngeal carcinoma cell line compared with the parental cell line (Cowan et al., 1982) ; and increased vincristine efflux and resistance by the activation of PKC in drug-sensitive MCF-7 cells . Indeed, the baseline PKC activity in K562/ADM cells is about 2-fold higher than that in K562 (unpublished data), and a phosphoprotein of about 20 kDa is observed only in K562/ADM cells labelled with 32P-ATP (unpublished data).
These findings suggest that decreased drug accumulation in K562/ADM may be associated with a change in phosphorylation of P-glycoprotein and/or 20 kDa phosphoprotein which is reversible by TPA-type tumour promoters. However, it is questionable whether a similar phenomenon occurs in PC-9/CDDP because increased drug efflux is not involved in the resistance of this line. K562/ADM and PC-9/CDDP also showed cross-resistance to okadaic acid which does not activate PKC. There was no difference in the accumulation of 3H-okadaic acid in the sensitive and the resistant cell lines. These results therefore suggest that the cross-resistance to okadaic acid in drug-resistant cells is not caused by changes in drug uptake and efflux. Recently, it has been demonstrated that okadaic acid can act on cells through inhibition of protein phosphatases which induced 'apparent' activation of protein kinases (Sassa et al., 1989) . Therefore, we consider that 'apparent' phosphorylation of cellular proteins might influence the drug sensitivity of cells. This is the first report demonstrating that adriamycin and cisplatin resistant cell lines each show cross-resistance to TPA-and non-TPA-type tumour promoters.
